ProQR Therapeutics (PRQR) Equity Ratio (2021 - 2025)

ProQR Therapeutics' Equity Ratio history spans 4 years, with the latest figure at 0.53 for Q4 2024.

  • For Q4 2024, Equity Ratio rose 75.65% year-over-year to 0.53; the TTM value through Dec 2024 reached 0.53, up 75.65%, while the annual FY2024 figure was 0.53, 75.65% up from the prior year.
  • Equity Ratio for Q4 2024 was 0.53 at ProQR Therapeutics, up from 0.3 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.54 in Q4 2021 and bottomed at 0.3 in Q4 2023.
  • The 4-year median for Equity Ratio is 0.46 (2022), against an average of 0.44.
  • The largest annual shift saw Equity Ratio decreased 28.51% in 2022 before it skyrocketed 75.65% in 2024.
  • A 4-year view of Equity Ratio shows it stood at 0.54 in 2021, then dropped by 28.51% to 0.39 in 2022, then decreased by 22.88% to 0.3 in 2023, then surged by 75.65% to 0.53 in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Equity Ratio are 0.53 (Q4 2024), 0.3 (Q4 2023), and 0.39 (Q4 2022).